Early double low-dose aspirin to help prevent preeclampsia and miscarriage
Official title: Early Double Low-Dose Aspirin to Reduce Preeclampsia and Miscarriage: a Global Approach RCT
Funded at University of Pennsylvania · NIH-11380015 · Data updated 2026-11-12
A large clinical trial tests whether starting a daily 162 mg aspirin as soon as pregnancy is detected can reduce both preeclampsia and pregnancy loss in early pregnancy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | August 10, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $662,066 |
| NIH project number | 5R01HD112308-04 |
| Project ID | NIH-11380015 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pregnant people in the very early stages of pregnancy (from first positive pregnancy test up to about 6 weeks gestation) who are eligible for participation at participating sites.
✕Less likely to help
Some participants may not experience a difference in outcomes or may encounter side effects from aspirin.
What this research studies
This trial invites people who might become pregnant to enroll if they test positive early, with aspirin taken from the moment of detection to see if it lowers risk of preeclampsia and miscarriage. It uses a randomized design to compare daily aspirin at a higher initial dose with standard care, while monitoring pregnancy outcomes. Participants will be followed through early pregnancy to track outcomes and safety. The study is led by the University of Pennsylvania and involves clinical centers and advisory committees to guide the trial conduct.
Why it matters
Potential benefit: If successful, the approach could reduce serious pregnancy complications and improve chances of a healthy pregnancy.
How similar studies have gone: Previous evidence supports aspirin for preeclampsia prevention, with newer data exploring earlier initiation and higher doses; this trial aims to confirm and extend those findings.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Schisterman, Enrique F. — University of Pennsylvania
- Study coordinator: Schisterman, Enrique F.
Related research
Other NIH-funded projects on the same topics.
-
Ethical, multimodal AI for predicting preeclampsia risk in early pregnancy
A data-driven AI tool uses early-pregnancy information from medical records, ultrasound, and notes to predict preeclampsia risk and support safer pregnancy care.
-
Placental support cells and fetal red blood cell quality in preeclampsia
This grant studies how placental support cells in preeclampsia affect the development and quality of a baby’s red blood cells.
-
Epigenetic clues to preeclampsia in pregnancy
This grant explores how epigenetic changes and paternal factors may contribute to preeclampsia, a condition that can affect pregnancy health.
-
Environmental air pollutants linked to preeclampsia risk in pregnancy
This study looks at whether common air pollutants called PAHs increase the risk of preeclampsia during pregnancy.
-
Dynamic risk prediction and subtyping of hypertensive disorders in pregnancy
A digital health approach uses AI to spot early warning signs of preeclampsia and gestational hypertension from pregnancy data, so clinicians can tailor care for pregnant people.
-
Folate Receptor Beta and its Role in Preeclampsia
This study explores how a protein called folate receptor beta on placental immune cells may drive or worsen preeclampsia in pregnancy, with hopes of finding new ways to prevent or treat the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.